Navidea Biopharmaceuticals announced results from two Phase 3 clinical trials of Lymphoseek (technetium 99m tilmanocept) Injection in patients with melanoma of the skin, assessing the performance of ...
Dysadherin Overexpression in Pancreatic Ductal Adenocarcinoma Reflects Tumor Aggressiveness: Relationship to E-Cadherin Expression Purpose: Sensitive detection methods and accurate reporting are ...
Navidea announced the launch of Lymphoseek (technetium Tc 99m tilmanocept) Injection for use in lymphatic mapping procedures that are performed to help in the diagnostic evaluation of potential cancer ...
September 11, 2012 — Approval of technetium (99m Tc)-tilmanocept for injection (Lymphoseek, Navidea), a product developed for intraoperative lymphatic mapping (ILM) in breast cancer and melanoma ...
(PhysOrg.com) -- Biomedical researchers at the University of Arkansas in Fayetteville and the University of Arkansas for Medical Sciences (UAMS) in Little Rock have developed a special ...
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and ...
Studies in breast cancer, melanoma, colon cancer, lung cancer and almost all solid malignancies that spread to lymph nodes have confirmed that metastatic cells move in an orderly manner from the ...
I placed the cold, jade rolling pin under my cheekbone and gently glided it to the edge of my face. To be honest, I felt a bit like a piece of pastry. But my grandma assured me that I was engaging in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results